Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up – Time to Buy?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $25.94, but opened at $27.6599. Chugai Pharmaceutical shares last traded at $26.62, with a volume of 5,376 shares changing hands.

Wall Street Analyst Weigh In

Several analysts recently issued reports on CHGCY shares. UBS Group upgraded shares of Chugai Pharmaceutical to a “strong-buy” rating in a research report on Tuesday, January 27th. Smbc Nikko Sec. upgraded shares of Chugai Pharmaceutical to a “strong-buy” rating in a research report on Wednesday, February 25th. Two equities research analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat, Chugai Pharmaceutical has an average rating of “Strong Buy”.

Chugai Pharmaceutical Price Performance

The stock has a market cap of $85.99 billion, a P/E ratio of 30.03 and a beta of 0.60. The stock has a 50-day simple moving average of $29.12 and a 200-day simple moving average of $26.38.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its earnings results on Thursday, January 29th. The company reported $0.25 EPS for the quarter. Chugai Pharmaceutical had a net margin of 34.47% and a return on equity of 22.00%. The firm had revenue of $2.25 billion during the quarter. As a group, sell-side analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.